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Abstract
Background—Experimental and epidemiologic data suggest that among non-pregnant adults, 
sleep duration may be an important risk factor for chronic disease. Although pregnant women 
commonly complain of poor sleep, few studies have objectively evaluated the quality of sleep in 
pregnancy or have explored the relationship between sleep disturbances and maternal and perinatal 
outcomes.
Objectives—Our objective was to examine the relationship between objectively assessed sleep 
duration, timing and continuity (measured via wrist actigraphy) and maternal cardiovascular and 
metabolic morbidity specific to pregnancy.
Study Design—This was a prospective cohort study of nulliparous women. Women were 
recruited between 16 0/7 and 21 6/7 weeks’ gestation. They were asked to wear a wrist actigraphy 
monitor and to complete a daily sleep log for a seven consecutive-day period. The primary sleep 
exposure variables were the averages of the following over the total valid nights (minimum 5, 
maximum 7 nights): short sleep duration during the primary sleep period (< 7 hours/night), late 
sleep midpoint (midpoint between sleep onset and sleep offset > 5 AM), and top quartile of 
minutes of wake time after sleep onset (WASO) and sleep fragmentation index. The primary 
outcomes of interest were a composite of hypertensive disorders of pregnancy (mild, severe, or 
superimposed preeclampsia; eclampsia; or antepartum gestational hypertension) and gestational 
diabetes (GDM). Chi-square tests were used to assess associations between sleep variables and 
categorical baseline characteristics. Crude odds ratios and 95% confidence intervals were 
estimated from univariate logistic regression models to characterize the magnitude of the 
relationship between sleep characteristics and hypertensive disorders of pregnancy and GDM. For 
associations that were significant in univariate analysis, multiple logistic regression was used to 
explore further the association of sleep characteristics with pregnancy outcomes.
Results—Nine-hundred and one eligible women consented to participate. Of these women 782 
submitted valid actigraphy studies. Short sleep duration and a later sleep midpoint were associated 
with an increased risk of GDM (OR 2.24, 95% CI 1.11, 4.53; OR 2.58, 95% CI 1.24, 5.36, 
respectively) but not of hypertensive disorders. A model with both sleep duration and sleep 
midpoint as well as their interaction term revealed that while there was no significant interaction 
between these exposures, the main effects of both short sleep duration and later sleep midpoint 
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with GDM remained significant (aOR 2.06, 95% CI 1.01, 4.19; aOR 2.37, 95% CI 1.13, 4.97, 
respectively). Additionally, after adjusting separately for age, BMI and race/ethnicity, both short 
sleep duration and later sleep midpoint remained associated with GDM. No associations were 
demonstrated between the sleep quality measures (WASO, sleep fragmentation) and hypertensive 
disorders or GDM.
Conclusions—Our results demonstrate a relationship between short sleep duration and later 
sleep midpoint with GDM. Our data suggest independent contributions of these two sleep 
characteristics to the risk for GDM in nulliparous women.
Condensation
Both objectively measured short sleep duration and later sleep timing are associated with 
development of gestational diabetes.
Keywords
Gestational diabetes; hypertension; pregnancy outcomes; sleep duration; sleep midpoint; sleep 
quality; actigraphy
Introduction
Experimental and epidemiologic data suggest that among non-pregnant adults, sleep 
duration is an important risk factor for chronic disease.[1–3] For example, short sleep 
duration has been linked to a higher frequency of hypertension and cardiovascular disease.
[4–7] There are particularly strong data suggesting that short sleep duration is associated 
with disordered metabolism and is linked to an increase in the risk of type 2 diabetes.[8–10] 
Long sleep duration has also been linked to cardiovascular and metabolic disease. [5, 8] 
While considerable research has focused on sleep duration, other aspects of sleep, including 
the timing of sleep and wake cycles and continuity of sleep, have been proposed as potential 
cardiometabolic risk factors.[11–14]
Hypertensive disease (e.g., preeclampsia) and metabolic disease (e.g., gestational diabetes 
mellitus) also can be acute complications during pregnancy. Hypertensive disorders of 
pregnancy and gestational diabetes are associated with maternal and perinatal morbidity and 
have long-term health consequences for both mothers and babies.[15, 16] Nevertheless, 
although pregnant women commonly complain of poor sleep,[17] few studies have 
objectively evaluated the duration, timing and quality of sleep in pregnancy and explored the 
relationship between objectively measured sleep and maternal and perinatal outcomes.[18–
25] Such a relationship is clinically relevant, as its existence may elucidate a modifiable 
factor for adverse pregnancy outcomes.
Therefore, our objective was to examine the relationship between objectively assessed sleep 
duration, timing and continuity (measured via actigraphy) and maternal cardiovascular and 
metabolic morbidity specific to pregnancy.
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Methods
This Sleep Duration and Continuity Study was conducted as a sub-study of the Nulliparous 
Pregnancy Outcome Study: Monitoring Mothers-to-be (nuMoM2b). NuMoM2b was an 
observational cohort study, conducted at 8 clinical sites and managed by a central data 
coordinating and analysis center.[26] The parent study protocol included nulliparous women 
of at least 13 years of age, although for this sub-study, those under the age of 18 were 
excluded given significant differences in adolescent versus adult sleep. In addition, while the 
parent study included women with chronic hypertension, these women were excluded from 
this sub-study given the difficulty in accurately diagnosing a new-onset hypertensive 
disorder in women with pre-existing hypertension. Women with pre-existing diabetes were 
also excluded as they cannot be diagnosed with gestational diabetes.
Women were recruited for this sleep sub-study at the parent study’s second study visit, 
which was scheduled between 16 0/7 and 21 6/7 weeks’ gestation. They were asked to wear 
a wrist actigraphy monitor (Spectrum, Philips Respironics, Figure 1) that records rest and 
activity periods and to complete a daily sleep log for the same seven consecutive-day period. 
Subjects were given up to 23 0/7 weeks to complete the 7 days of actigraphy and sleep log 
data collection. For the sleep log, participants were asked to note bedtime, wake-up time, 
total sleep time, sleep latency, wake after sleep onset, naps, any unusual events during the 
sleep period, and overall sleep quality. Actigraphy provides an objective measure of rest-
activity patterns from which various measures of sleep duration, quality and timing can be 
determined daily. Studies have shown that there is good correlation between wrist actigraphy 
and polysomnographic (PSG) recorded sleep.[27] In addition, actigraphy provides the ability 
to collect sleep-wake information over many consecutive days, unlike PSG, in a simple, 
reliable and cost-effective manner. Obtaining an objective evaluation of sleep is important 
because data suggests that there is only a moderate correlation between self-reported and 
actigraphically recorded sleep, particularly among those with more disrupted sleep patterns.
[28, 29]
An actigraphy recording was considered successful if there was a minimum of 5 days 
recorded and if within the five days there was less than 4 hours of off-wrist time per 24-hour 
period and no off-wrist signal during the time the subject indicated she was in bed. If a 
participant’s recording did not meet these criteria, she was asked if she would be willing to 
wear the watch for another 7-day period if the total recording could be completed by 23 0/7 
weeks.
All actigraph files and sleep log data were securely transmitted to a central actigraphy 
reading center. The complete sleep scoring and quality control protocol has been described 
previously.[30] The primary sleep exposure variables for this analysis were the averages of 
the following over the total valid nights (minimum 5, maximum 7 nights): sleep duration 
during the primary sleep period, sleep midpoint (the midpoint between sleep onset and sleep 
offset), minutes of wake time after sleep onset (WASO) and sleep fragmentation index. 
These variables are defined in greater detail in Table 1. Based on a review of available data 
detailing the relationship between sleep in non-pregnant populations and health outcomes, a 
cut-off of less than 7 hours for sleep duration was defined a priori as “short sleep duration”
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[31], Similarly, a cutoff of later than 5 AM was defined a priori as a “late sleep midpoint”.
[32, 33] As there are no well-established, clinically-relevant cut-offs for actigraphy defined 
WASO and sleep fragmentation, these continuous variables were transformed into quartiles; 
women were categorized based on these quartiles, with women in the quartiles representing 
the longest WASO and the greatest sleep fragmentation considered to have the most 
disturbed, poorest quality, sleep.
At least 30 days after delivery, a trained, certified chart abstractor assessed all participants’ 
medical records to record birth outcomes and readmissions to the hospital. The primary 
outcomes of interest were 1) a composite of hypertensive disorders of pregnancy (mild or 
severe preeclampsia; eclampsia; or antepartum gestational hypertension) and 2) gestational 
diabetes (GDM). For any participant with documented hypertension or proteinuria a detailed 
chart abstraction was performed that included assessment of blood pressure severity, new-
onset neurologic disturbances, epigastric pain or pulmonary edema, and blood and urine 
laboratory results. Supplement S1 (online) outlines study definitions for types of 
hypertensive disorders. Cases that presented atypically and were difficult to classify 
according to study criteria were adjudicated by review of clinical data by the principal 
investigators and final classification was reached by their consensus judgment.
All glucose tolerance testing (GTT) was performed as part of routine clinical care. A woman 
was considered to have GDM if she met one of the following GTT criteria: 1) fasting 3-hour 
100 gram GTT with two of the following values: fasting ≥95 mg/dL, 1-hour ≥180 mg/dL, 2-
hour ≥155 mg/dL, 3-hour ≥140 mg/dL; 2) fasting 2-hour 75 gram GTT with one of the 
following values: fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥153 mg/dL; 3) non-
fasting 50 gram GTT with a one-hour value ≥ 200 mg/dL if no fasting 3-hour or 2-hour GTT 
was performed. In addition to GTT data, chart abstractors recorded if a diagnosis of GDM 
was made during the course of clinical care. If no GTT data were available the diagnosis of 
GDM based on chart abstraction was used for GDM classification.
A detailed description of our sample size calculation has been previously published.[30] In 
summary, assuming, as described in non-pregnant US populations, a “short sleep duration” 
prevalence of 25%, an outcome prevalence of at least 8% for pregnancy related hypertension 
or GDM, and an alpha error of < 5%, a sample size of 760 women would provide at least 
80% power to detect a 2-fold increase in the risk of the adverse pregnancy outcomes among 
women with short sleep durations.[34]
Descriptive statistics were used to characterize the study population by dichotomous sleep 
variables (sleep duration <7 hours, WASO ≥ 75th percentile, sleep fragmentation index ≥ 
75th percentile, and sleep midpoint later than 5 AM). Chi-square tests were used to assess 
the associations between sleep variables and categorical baseline characteristics. Kruskal-
Wallis tests were used to compare the distribution of sleep variables for categories of 
baseline characteristics. Spearman correlation coefficients were used to assess relationships 
between sleep variables. Crude odds ratios and 95% confidence intervals were estimated 
from univariate logistic regression models to characterize the magnitude of the relationship 
between sleep characteristics and hypertensive disorders of pregnancy and GDM. For 
associations that were significant in univariate analysis, multiple logistic regression was used 
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to explore further the association of sleep characteristics with pregnancy outcomes after 
adjustment for baseline characteristics. Adjustment covariates that were chosen a priori 
included maternal age and early pregnancy body mass index (BMI), treated as continuous 
variables and maternal race/ethnicity. Self-reported frequent snoring (a common symptom of 
sleep apnea), defined as pre-pregnancy snoring at least 3–4 times/week, and employment 
schedule were also chosen as covariates given their association with our sleep variables and 
pregnancy outcomes. Linear and quadratic terms were included for age and BMI to help 
ensure that their relationships with the outcome were fully accounted for in the adjustment. 
Multiple logistic regression was also used post hoc to consider interactions between two 
sleep characteristics on pregnancy outcomes, and to assess their independent association 
with GDM. Initial models included main effects and interaction, but were reduced to main 
effects in the absence of a significant interaction.
All tests were performed at a nominal significance level of α=0.05 with two-sided, single 
degree-of-freedom tests. No correction was made for multiple comparisons. Analyses were 
conducted using SAS 9.3/9.4 software. This study was approved the Institutional Review 
Board at each center, and all women provided informed written consent prior to enrollment.
Results
Nine-hundred and one eligible women consented to participate. Of these women, 782 
submitted valid actigraphy studies and form the basis of this analysis. The median 
gestational age at recruitment (study visit 2) was 19 1/7 weeks’ gestation (range 15 6/7 – 22 
5/7 weeks of gestation). The median gestational age at delivery was 39 5/7 weeks’ gestation 
(range 21 0/7 – 42 4/7 weeks of gestation). The rate of hypertensive disorders was 11.6%. 
Specifically, the rate of preeclampsia was 4.9% (38/782); the rate of antepartum gestational 
hypertension was 6.8% (53/782). The rate of gestational diabetes was 4.2%. The large 
majority of women (n= 699, 94.3%) completed their GTT more than 1 week after the 
actigraphy study. Forty-two women (5.7%) completed their GTT testing before the objective 
evaluation of sleep duration (only 16/42 were performed before 13 weeks); only 4 of these 
42 women were diagnosed with GDM.
Sleep duration of < 7 hours was present in 27.9% of the participants. Only 3.5% and 2.6% of 
women had sleep durations of < 6 hours or ≥ 9 hours, respectively. 18.9% of women had a 
sleep midpoint later than 5 AM. Participant characteristics stratified by different sleep 
metrics are shown in Table 2. Short sleep duration was significantly associated with race/
ethnicity and BMI. The upper quartiles of WASO and sleep fragmentation were associated 
with most baseline demographics, with the exception of self-reported frequent snoring and 
prior sleep disorder history (sleep apnea, insomnia, restless legs syndrome). Late sleep 
timing was associated with all characteristics with the exception of prior history of restless 
legs syndrome. Of note, we found that women who worked regular day shifts had 
significantly earlier sleep midpoints [N= 441, median (Q1: 25th percentile, Q3: 75th 
percentile) sleep midpoint 3:10 AM (2:40 AM, 3:51 AM)] compared to women who 
reported working some form of shift work [N=148 median (Q1, Q3) sleep midpoint 4:14 
AM (3:22 AM, 5:39 AM)] or who were unemployed [N=152 median (Q1, Q3) sleep 
midpoint 4:34 AM (3:45 AM, 5:37AM)], Kruskal-Wallis test p<0.0001.
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The relationship between sleep metrics and hypertensive disorders of pregnancy and GDM 
are shown in Table 3. Short sleep duration and a later sleep midpoint were associated with an 
increased risk of GDM (OR 2.24, 95% CI 1.11, 4.53; OR 2.58, 95% CI 1.24, 5.36, 
respectively) but not hypertensive disorders. When we repeated the sleep duration and 
midpoint analyses excluding women whose GDM status was ascertained only through 
diagnosis from chart abstraction but without a documented GTT (N =44), the odds ratios and 
p-values did not change appreciably (data not shown). No associations were demonstrated 
between the sleep quality measures (WASO, sleep fragmentation) and hypertensive disorders 
or GDM.
Given the significant findings between both sleep duration and sleep midpoint in relation to 
GDM, we examined the relationship of sleep duration with sleep midpoint, and found that 
they were not correlated in our cohort (Spearman correlation coefficient 0.02, P=0.67). A 
logistic regression model with both sleep duration and sleep midpoint as well as their 
interaction term revealed that while there was no significant interaction between these 
exposures, the main effects of both short sleep duration and later sleep midpoint with GDM 
were significant (aOR 2.06, 95% CI 1.01, 4.19; aOR 2.37, 95% CI 1.13, 4.97, respectively).
With 33 cases of GDM, multiple covariate adjustment would risk model overfitting. 
Therefore, to further examine the relationship of short sleep duration and late sleep midpoint 
with gestational diabetes, taking into account potential confounders, we performed a series 
of regression analyses with single variable adjustments. After adjusting separately for age, 
BMI, race/ethnicity and employment schedule, both short sleep duration and sleep midpoint 
remained associated with GDM (Table 4). After adjusting for self-reported frequent snoring, 
sleep midpoint remained significantly associated with GDM; the magnitude of the effect of 
short sleep duration with GDM was similar to that seen in the other unadjusted and adjusted 
analyses, although the p-value just exceeded 0.05 (aOR 2.29, 95% CI 0.97, 5.39; p-value = 
0.059).
Conclusions
Our data demonstrate that, among nulliparous women, both sleep duration and timing of 
sleep in the second trimester are associated with the development of GDM. Specifically, 
mean sleep duration of less than 7 hours per night was associated with an approximate 2-
fold increase in the odds of GDM, and this association was independent of age, BMI, race/
ethnicity and self-reported frequent snoring. Similarly, a later sleep midpoint (after 5 AM) 
was associated with an increased risk of GDM, and our data suggest that this increase was 
independent of sleep duration. We did not detect any relationship between measures of sleep 
duration, timing or sleep quality and hypertensive disorders of pregnancy.
While laboratory studies demonstrate that experimentally fragmented sleep alters glucose 
metabolism, adrenocortical function and sympathovagal balance,[11] in our study, sleep 
quality, as measured by WASO and sleep fragmentation, was not associated with maternal 
increased cardiovascular and metabolic morbidity. However, our negative results should be 
considered with caution. The degree of WASO disturbance and sleep fragmentation were 
categorized by quartiles as there are no other well established, clinically relevant cut-offs for 
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these sleep characteristics in pregnancy, and it is possible our sample size did not allow for 
the examination of more severe, but less common, phenotypes.
The major strengths of this study are the use of actigraphy to obtain a weeklong objective 
recording of rest/activity in coordination with a central and blinded actigraphy reading 
center. The study population is diverse in terms of age, race, ethnicity, BMI and socio-
economic measures, making our findings more generalizable. Nevertheless, given our 
onetime assessment of objectively measures sleep, we were not able to examine whether 
changes in sleep patterns and quality throughout pregnancy also may be associated with 
pregnancy outcomes. And while some studies suggest that long sleep duration (at least 9 
hours) is also a risk factor for cardiovascular and metabolic disease, we were not able to 
examine the association between long sleep duration and hypertensive disorders and GDM 
due to the very small proportion of women who had sleep durations in this range (2.6%). 
Finally, given the observational design, there is always the possibility of residual 
confounding from unmeasured variables or a limit in the extent to which even measured 
confounders can be assessed.
In non-pregnant populations, several large, prospective cohort studies examined the 
association between sleep duration and incident type 2 diabetes, although the majority relied 
on self-reported sleep assessments. Most of these studies reported increased odds of diabetes 
associated with short sleep duration. In two independent pooled analyses of prospective 
studies, an association between short sleep and incident type 2 diabetes was documented, 
with odds ratio 1.33 (95% CI 1.20, 1.48) and relative risk 1.28 (95% CI 1.03, 1.60) reported.
[8, 9] Data from pregnancy cohorts, both prospective and retrospective, using self-reported 
sleep duration have also suggested that short sleep is a risk factor for GDM.[35–37] In one 
study of 63 pregnant women who wore an actigraph in mid-pregnancy, objectively measured 
short sleep was associated with higher values on 1-hour GTT screening tests.[21] Our data 
are consistent with and extend the findings of these previous reports, confirming that short 
sleep duration, as objectively measured by actigraphy, is associated with incident GDM in a 
large population of nulliparous women. Our study is the largest to date in which objective 
measures of sleep duration in pregnancy were obtained. Furthermore, by excluding women 
with pre-gestational diabetes, rigorously defining GDM, and by measuring sleep duration 
prior to 24 weeks, we optimized case ascertainment and ensured that our exposure variable 
pre-dated the diagnosis in the vast majority of our subjects.
Compared to diabetes, the association between sleep duration and chronic hypertension is 
less consistent in non-pregnant individuals. Cross-sectional studies generally demonstrate a 
higher rate of hypertension among short sleepers, but data from longitudinal cohorts are 
conflicting.[38]. Limited data on the association of sleep duration measures with 
hypertension in pregnancy are similarly conflicting. [20, 39] In our study of nulliparous 
women that excluded women with chronic hypertension, we failed to demonstrate a 
relationship between sleep duration and pregnancy-related hypertension. We were powered 
to detect an approximately 2-fold increase in risk, but cannot rule out the possibility of a 
more modest risk relationship.
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In addition to sleep duration and continuity, the timing of sleep as a marker of circadian 
timing is emerging as a risk factor for cardiometabolic health.[32] Later sleep timing is often 
associated with circadian misalignment. This misalignment can occur when sleep and 
wakefulness behaviors do not occur at an appropriate time relative to the timing of the 
central circadian clock (hypothalamus) and/or relative to the external environment (light-
dark cycle). A large survey study demonstrated that, when free from occupation and social 
obligations, the most commonly reported sleep timing is approximately midnight to 8:00 
AM.[32] However, work and social demands as well as environmental influences, can lead 
to alterations in sleep timing and circadian disruption. Experimental studies show that sleep 
misaligned with the timing of endogenous circadian rhythms is linked to alterations in leptin 
and glucose and increased mean arterial pressure. [40] In addition, being awake later at night 
has been linked to poorer health behaviors such as greater fast-food consumption and 
increased alcohol use.[12, 41] Epidemiologic data link shift-work to an increased risk of 
obesity, type 2 diabetes and cardiovascular disease.[42–44] Our study examined sleep timing 
in pregnancy (i.e., sleep midpoint) as a risk factor for adverse pregnancy outcomes. We 
found that both having a shift-work schedule and being unemployed while pregnant were 
associated with a later sleep midpoint (> 5 AM) and we demonstrated a strong association 
between later sleep timing and GDM that was independent of sleep duration and other 
confounders.
In conclusion, we found a relationship between short sleep duration and later sleep timing 
with GDM in nulliparous women. Our data suggest independent contributions of these two 
sleep characteristics to the risk for GDM. Identifying and addressing modifiable risks factors 
for GDM is important as GDM is associated with an increased risk of preeclampsia, fetal 
macrosomia, birth trauma, and neonatal metabolic complications.[45] Based on our data, 
sleep, like diet and exercise, should be considered a modifiable behavior that has potential 
health implications for pregnancy. Although this is an observational study, it is biologically 
plausible that the relationship may be causal. Yet, the mechanisms by which sleep duration 
and timing may impact metabolism in pregnancy are likely multifactorial and further 
research is needed to better understand the biology of sleep in pregnancy and whether 
interventions in early pregnancy to address sleep duration and schedule can modify the risk 
of GDM.
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Figure 1. 
Actiwatch Spectrum (Philips Respironics)
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Table 1
Sleep variable definitions
Variable name Variable description
Sleep duration (hours) • Sleep duration was defined as the total amount of time scored as sleep during the main designated 
rest period each day.
• The sleep duration for each available day (5–7 days) were then averaged.
• The cut off of an average sleep duration of < 7 hours was chosen based on prior data in pregnant 
women from the authors and on recommendations for adequate sleep duration recently published 
by the American Academy of Sleep Medicine.
Sleep midpoint (hh:mm) • Sleep midpoint is the clock time that represents the midpoint between the clock time of sleep onset 
and the clock time of sleep offset.
• The sleep midpoint was calculated for each valid day then averaged for each available day (5–7 
days).
• The cut off of an average sleep midpoint later than 5am was chosen a priori based on large samples 
of population based self-reported data.
Wake after sleep onset 
(minutes)
• Wake after sleep onset (WASO) is the total amount of minutes spent awake between sleep onset 
and the end of the rest interval.
• The minutes of WASO were calculated for each valid day then averaged for each available day (5–
7 days).
• Given that there are no well-established actigraphy based cutoffs for WASO, the data were divided 
into quartiles and those with an average WASO ≥ 75th percentile were considered to have poor 
sleep.
Sleep fragmentation (%) • The sleep fragmentation index (FI) is calculated as the proportion of all epochs from sleep onset to 
sleep offset with an activity count of 2 or greater plus the proportion of all bouts of immobility 
(activity count less than 2 in every epoch) that were 1 minute or less in duration.
• The FI was determined for each valid day then averaged for each available day (5–7 days).
• Given that there are no well-established actigraphy based cutoffs for FI, the data were divided into 
quartiles and those with an average FI ≥ 75th percentile were considered to have poor sleep.
Am J Obstet Gynecol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Facco et al. Page 14
Ta
bl
e 
2
Pe
rc
en
ta
ge
 o
f w
o
m
en
 in
 w
o
rs
t c
at
eg
or
y 
of
 sl
ee
p 
m
ea
su
re
s a
cc
or
di
ng
 to
 p
ar
tic
ip
an
t c
ha
ra
ct
er
ist
ic
s
Ba
se
lin
e 
C
ha
ra
ct
er
ist
ic
Sa
m
pl
e
Si
ze
Sl
ee
p 
D
ur
at
io
n 
< 
7
ho
ur
s
W
A
SO
 ≥
 7
5t
h
pe
rc
en
til
ea
Sl
ee
p 
Fr
ag
m
en
ta
tio
n
In
de
x 
≥ 
75
th
 p
er
ce
n
til
ea
Sl
ee
p 
M
id
po
in
t >
 5
 A
M
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
O
ve
ra
ll
78
2
21
8 
(27
.9)
19
6 
(25
.1)
19
6 
(25
.1)
14
8 
(18
.9)
M
at
er
na
l a
ge
, i
n 
ye
ar
s
 
 
<
22
14
8
41
 (2
7.7
)
0.
95
71
60
 (4
0.5
)
<
.0
00
1
56
 (3
7.8
)
0.
00
01
57
 (3
8.5
)
<
.0
00
1
 
 
22
 to
 3
5
57
3
15
9 
(27
.7)
12
1 
(21
.1)
12
2 
(21
.3)
86
 (1
5.0
)
 
 
>
35
61
18
 (2
9.5
)
15
 (2
4.6
)
18
 (2
9.5
)
5 
(8.
2)
R
ac
e/
et
hn
ic
ity
 
 
W
hi
te
 N
on
-H
isp
an
ic
49
6
11
0 
(22
.2)
<
.0
00
1
89
 (1
7.9
)
<
.0
00
1
90
 (1
8.1
)
<
.0
00
1
64
 (1
2.9
)
<
.0
00
1
 
 
B
la
ck
 N
on
-H
isp
an
ic
92
40
 (4
3.5
)
42
 (4
5.7
)
47
 (5
1.1
)
28
 (3
0.4
)
 
 
H
isp
an
ic
12
2
39
 (3
2.0
)
42
 (3
4.4
)
37
 (3
0.3
)
40
 (3
2.8
)
 
 
A
sia
n
28
14
 (5
0.0
)
9 
(32
.1)
8 
(28
.6)
4 
(14
.3)
 
 
O
th
er
44
15
 (3
4.1
)
14
 (3
1.8
)
14
 (3
1.8
)
12
 (2
7.3
)
B
M
I, 
in
 k
g/
m
2
 
 
<
25
41
2
10
9 
(26
.5)
0.
02
09
89
 (2
1.6
)
0.
00
86
92
 (2
2.3
)
0.
02
41
68
 (1
6.5
)
0.
01
10
 
 
25
 to
 <
30
19
4
46
 (2
3.7
)
46
 (2
3.7
)
47
 (2
4.2
)
34
 (1
7.5
)
 
 
≥3
0
16
6
60
 (3
6.1
)
56
 (3
3.7
)
55
 (3
3.1
)
45
 (2
7.1
)
Em
pl
oy
m
en
t/s
ch
oo
l s
ta
tu
s
 
 
Em
pl
oy
ed
 a
nd
 in
 sc
ho
ol
11
6
30
 (2
5.9
)
0.
94
66
28
 (2
4.1
)
<
.0
00
1
25
 (2
1.6
)
0.
03
82
14
 (1
2.1
)
<
.0
00
1
 
 
Em
pl
oy
ed
 a
nd
 n
ot
 in
 sc
ho
ol
47
4
13
2 
(27
.8)
99
 (2
0.9
)
10
9 
(23
.0)
57
 (1
2.0
)
 
 
U
ne
m
pl
oy
ed
 a
nd
 in
 sc
ho
ol
48
14
 (2
9.2
)
20
 (4
1.7
)
14
 (2
9.2
)
14
 (2
9.2
)
 
 
U
ne
m
pl
oy
ed
 a
nd
 n
ot
 in
 sc
ho
ol
10
4
27
 (2
6.0
)
42
 (4
0.4
)
37
 (3
5.6
)
47
 (4
5.2
)
B
el
ow
 P
ov
er
ty
 L
ev
el
 
 
Ye
s
17
9
49
 (2
7.4
)
0.
64
57
72
 (4
0.2
)
<
.0
00
1
61
 (3
4.1
)
<
.0
00
1
55
 (3
0.7
)
<
.0
00
1
 
 
N
o
46
1
11
8 
(25
.6)
71
 (1
5.4
)
85
 (1
8.4
)
42
 (9
.1)
Ed
uc
at
io
n 
sta
tu
s
 
 
Le
ss
 th
an
 h
ig
h 
sc
ho
ol
28
8 
(28
.6)
0.
36
23
16
 (5
7.1
)
<
.0
00
1
12
 (4
2.9
)
<
.0
00
1
12
 (4
2.9
)
<
.0
00
1
 
 
Co
m
pl
et
ed
 h
ig
h 
sc
ho
ol
 o
r G
ED
89
29
 (3
2.6
)
40
 (4
4.9
)
42
 (4
7.2
)
43
 (4
8.3
)
Am J Obstet Gynecol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Facco et al. Page 15
Ba
se
lin
e 
C
ha
ra
ct
er
ist
ic
Sa
m
pl
e
Si
ze
Sl
ee
p 
D
ur
at
io
n 
< 
7
ho
ur
s
W
A
SO
 ≥
 7
5t
h
pe
rc
en
til
ea
Sl
ee
p 
Fr
ag
m
en
ta
tio
n
In
de
x 
≥ 
75
th
 p
er
ce
n
til
ea
Sl
ee
p 
M
id
po
in
t >
 5
 A
M
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
n
 (%
)
p-
va
lu
eb
 
 
So
m
e 
co
lle
ge
17
6
55
 (3
1.3
)
53
 (3
0.1
)
45
 (2
5.6
)
44
 (2
5.0
)
 
 
A
ss
oc
ia
te
 o
r t
ec
hn
ic
al
 d
eg
re
e
87
25
 (2
8.7
)
26
 (2
9.9
)
22
 (2
5.3
)
14
 (1
6.1
)
 
 
Co
m
pl
et
ed
 c
ol
le
ge
21
0
59
 (2
8.1
)
39
 (1
8.6
)
45
 (2
1.4
)
26
 (1
2.4
)
 
 
D
eg
re
e 
w
o
rk
 b
ey
on
d 
co
lle
ge
19
2
42
 (2
1.9
)
22
 (1
1.5
)
30
 (1
5.6
)
9 
(4.
7)
Sm
ok
ed
 d
ur
in
g 
3 
m
on
th
s p
rio
r t
o 
pr
eg
na
nc
y:
 
 
Ye
s
11
3
38
 (3
3.6
)
0.
14
05
38
 (3
3.6
)
0.
02
31
39
 (3
4.5
)
0.
01
22
46
 (4
0.7
)
<
.0
00
1
 
 
N
o
66
9
18
0 
(26
.9)
15
8 
(23
.6)
15
7 
(23
.5)
10
2 
(15
.2)
Fr
eq
ue
nt
 sn
or
in
g 
be
fo
re
 p
re
gn
an
cy
c :
 
 
Ye
s
96
29
 (3
0.2
)
0.
47
49
29
 (3
0.2
)
0.
13
86
28
 (2
9.2
)
0.
19
25
25
 (2
6.0
)
0.
01
30
 
 
N
o
57
3
15
3 
(26
.7)
13
3 
(23
.2)
13
2 
(23
.0)
90
 (1
5.7
)
Em
pl
oy
m
en
t s
ch
ed
ul
ec
:
 
 
R
eg
ul
ar
 d
ay
 sh
ift
44
1
12
1 
(27
.4)
0.
98
95
80
 (1
8.1
)
<
.0
00
1
92
 (2
0.9
)
0.
00
44
21
 (4
.8)
<
.0
00
1
 
 
So
m
e 
fo
rm
 o
f s
hi
ft 
w
o
rk
d
14
8
41
 (2
7.7
)
47
 (3
1.8
)
42
 (2
8.4
)
50
 (3
3.8
)
 
 
U
ne
m
pl
oy
ed
15
2
41
 (2
7.0
)
62
 (4
0.8
)
51
 (3
3.6
)
61
 (4
0.1
)
Ev
er
 d
ia
gn
os
ed
 w
ith
 sl
ee
p 
ap
ne
ac
:
 
 
Ye
s
12
4 
(33
.3)
0.
74
47
5 
(41
.7)
0.
19
55
6 
(50
.0)
0.
08
37
5 
(41
.7)
0.
04
41
 
 
N
o/
D
on
't 
kn
ow
72
4
19
8 
(27
.3)
18
3 
(25
.3)
17
8 
(24
.6)
12
5 
(17
.3)
Ev
er
 d
ia
gn
os
ed
 w
ith
 in
so
m
ni
ac
:
 
 
Ye
s
28
6 
(21
.4)
0.
66
57
9 
(32
.1)
0.
50
74
8 
(28
.6)
0.
65
94
10
 (3
5.7
)
0.
01
94
 
 
N
o/
D
on
't 
kn
ow
70
9
19
6 
(27
.6)
18
0 
(25
.4)
17
7 
(25
.0)
12
0 
(16
.9)
Ev
er
 d
ia
gn
os
ed
 w
ith
 re
stl
es
s l
eg
s s
yn
dr
om
ec
:
 
 
Ye
s
10
1 
(10
.0)
0.
29
99
4 
(40
.0)
0.
28
71
2 
(20
.0)
1.
00
00
2 
(20
.0)
0.
69
23
 
 
N
o/
D
on
't 
kn
ow
72
6
20
1 
(27
.7)
18
4 
(25
.3)
18
2 
(25
.1)
12
8 
(17
.6)
a A
 c
ut
of
f o
f 5
6.
0 
m
in
ut
es
 fo
r W
A
SO
 is
 th
e 
up
pe
r 2
5t
h  
pe
rc
en
til
e.
 A
 c
ut
of
f o
f 2
1.
4%
 fo
r s
le
ep
 fr
ag
m
en
ta
tio
n 
is 
th
e 
up
pe
r 2
5t
h  
pe
rc
en
til
e.
b P
-v
al
ue
s a
re
 sh
ow
n
 fr
om
 C
hi
-s
qu
ar
e 
te
sts
.
c D
at
a 
co
lle
ct
ed
 b
y 
su
rv
ey
 d
on
e 
as
 p
ar
t o
f t
he
 n
uM
oM
2b
 p
ar
en
t s
tu
dy
,
 
ad
m
in
ist
er
ed
 b
et
w
ee
n 
60
–
15
0  
w
ee
ks
 o
f p
re
gn
an
cy
Am J Obstet Gynecol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Facco et al. Page 16
d S
el
f-r
ep
or
te
d 
us
ua
l w
o
rk
 sc
he
du
le
 d
es
cr
ib
ed
 a
s o
ne
 o
f t
he
 fo
llo
w
in
g:
 n
ig
ht
 sh
ift
, s
pl
it 
sh
ift
, a
fte
rn
oo
n 
sh
ift
, i
rre
gu
la
r s
hi
ft/
on
 c
al
l o
r r
ot
at
in
g 
sh
ift
Am J Obstet Gynecol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Facco et al. Page 17
Table 3
Association of sleep duration, continuity and timing with hypertensive disease of pregnancy and gestational 
diabetes
Hypertensive disease of pregnancy Gestational Diabetes
Sleep characteristic N(%) Crude OR N(%) Crude OR
Sleep Duration
  <7 hours 27/218 (12.4) 1.10 (0.68, 1.78) 15/218 (6.9) 2.24 (1.11, 4.53)
  ≥7 hours 64/564 (11.3) 1.00 18/564 (3.2) 1.00
p-value = 0.6850 p-value = 0.0246
Sleep Midpoint
  >5 AM 17/148 (11.5) 0.98 (0.56, 1.72) 12/148 (8.1) 2.58 (1.24, 5.36)
  ≤5 AM 74/634 (11.7) 1.00 21/634 (3.3) 1.00
p-value = 0.9497 p-value = 0.0114
WASO
  ≥75th percentilea 27/196 (13.8) 1.30 (0.80, 2.11) 10/196 (5.1) 1.32 (0.62, 2.82)
  <75th percentile 64/586 (10.9) 1.00 23/586 (3.9) 1.00
p-value = 0.2816 p-value = 0.4789
Sleep Fragmentation Index
  ≥75th percentilea 25/196 (12.8) 1.15 (0.70, 1.88) 10/196 (5.1) 1.32 (0.62, 2.82)
  <75th percentile 66/586 (11.3) 1.00 23/586 (3.9) 1.00
p-value = 0.5730 p-value = 0.4789
aA cutoff of 56.0 minutes for WASO is the upper 25th percentile. A cutoff of 21.4% for sleep fragmentation is the upper 25th percentile.
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